Welcome to our dedicated page for Anika Therapeutics news (Ticker: ANIK), a resource for investors and traders seeking the latest updates and insights on Anika Therapeutics stock.
Anika Therapeutics Inc (ANIK) specializes in innovative orthopedic solutions using hyaluronic acid technology for joint preservation and regenerative therapies. This news hub provides investors and healthcare professionals with essential updates on the company's clinical advancements and strategic initiatives.
Access timely press releases covering regulatory milestones, financial results, and product developments. Our curated collection includes updates on osteoarthritis pain management innovations, surgical partnership expansions, and research breakthroughs in tissue repair technologies.
Key content categories feature earnings announcements, FDA clearances, OEM collaborations, and clinical trial outcomes. All information is sourced directly from the company to ensure accuracy and compliance with financial disclosure standards.
Bookmark this page for streamlined access to ANIK's latest medical technology updates and market-moving developments. Check regularly for authoritative information supporting informed analysis of the company's position in the orthopedic sector.
Anika Therapeutics (NASDAQ: ANIK), a global joint preservation company specializing in early intervention orthopedics, has scheduled the release of its first quarter 2025 financial results before market opening on Friday, May 9, 2025.
The company will host a conference call at 8:30 a.m. ET to discuss the results and business highlights. Investors can join via phone using toll-free domestic (1-800-717-1738) or international (1-646-307-1865) numbers with conference ID 63463. A live audio webcast with presentation materials will be available on Anika's website investor relations section.
Anika Therapeutics (NASDAQ: ANIK) has announced the granting of non-statutory stock options to a newly hired non-executive employee on April 1, 2025. The options cover 3,800 shares of common stock with an exercise price of $15.03 per share, matching the closing price on Nasdaq Global Select Market on the grant date.
The options were granted under the Anika Therapeutics 2021 Inducement Plan and approved by the compensation committee. The vesting schedule includes one-third of the shares vesting on each of the first three anniversaries of the grant date, contingent on continuous service. The options will expire after ten years and were granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Anika Therapeutics (NASDAQ: ANIK) reported Q4 2024 revenue of $30.6 million, up 1% year-over-year, with full-year 2024 revenue at $119.9 million, down 1% from 2023.
The Commercial Channel showed strong performance with 25% growth in Q4 and 17% annual growth, driven by the Integrity Implant System (>40% sequential growth) and International OA Pain Management. The OEM Channel declined 8% as expected.
Key highlights include:
- Over 300 Integrity surgeries performed in Q4, totaling 1,000+ globally since launch
- Filed second PMA module for Hyalofast with US launch anticipated by 2026
- Completed sale of Parcus Medical to focus on core HA products
- Completed $15M share repurchase program ahead of schedule
For 2025 guidance, Anika expects Commercial Channel revenue growth of 12-18% ($47-49.5M) and OEM Channel revenue decline of 12-18% ($64-68.5M). Adjusted EBITDA margin is projected at 8-10%.
Anika Therapeutics (NASDAQ: ANIK) has completed the divestiture of its Parcus Medical business to Medacta Group SA on March 7, 2025. The transaction was completed with total cash consideration received at closing, subject to customary post-closing adjustments.
This strategic move aligns with Anika's previously announced strategic review, allowing the company to sharpen its focus on its core hyaluronic acid technology and advance its Regenerative Solutions portfolio in early intervention orthopedics.
Both companies have committed to ensuring a smooth transition for employees, distributor agents, surgeon customers, and patients. Goodwin Procter served as legal counsel and Piper Sandler acted as exclusive financial advisor to Anika for the transaction.
Anika Therapeutics (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, has scheduled its fourth quarter and year-end 2024 financial results announcement for Wednesday, March 12, 2025, after market close.
The company will host an investor conference call at 5:00 p.m. ET on the same day to discuss financial results and business highlights. Investors can join via phone using the toll-free domestic number 1-800-717-1738 or international number 1-646-307-1865 with conference ID 89368. A live audio webcast and presentation materials will be available on Anika's website investor relations section.
Anika Therapeutics (NASDAQ: ANIK), a global joint preservation company focusing on early intervention orthopedics, has announced that its President and CEO, Dr. Cheryl Blanchard, will be presenting at the Canaccord Genuity 2025 Musculoskeletal Conference in San Diego.
The presentation is scheduled for Monday, March 10, 2025, at 2:30 PM PT / 5:30 PM ET. In addition to the presentation, Anika's management team will be participating in one-on-one investor meetings throughout the event.
Interested parties can access a live webcast of the presentation on the Events and Webcasts page under the Investors section of Anika's website. The presentation will remain archived on the site for 30 days afterward. Investors seeking to schedule meetings with Anika's senior management during the conference can contact the company's Investor Relations department at investorrelations@anika.com.
Anika Therapeutics (NASDAQ: ANIK), a global joint preservation company specializing in early intervention orthopedics, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Dr. Cheryl Blanchard, President and CEO, will deliver a presentation on Thursday, January 16, 2025, at 9:45am PT / 12:45pm ET in San Francisco.
The presentation will be accessible via live webcast on the Events and Webcasts page in the Investors section of Anika's website, remaining available for 30 days afterward. The company's management team will also engage in one-on-one investor meetings throughout the event. Interested parties can arrange meetings through Anika's Investor Relations.
Anika Therapeutics (NASDAQ: ANIK), a global joint preservation company, announced its participation in three major investor conferences this December. The company will attend the 36th Annual Piper Sandler Healthcare Conference in New York on December 3rd, with a presentation at 10:30am ET. They will also participate in the Sidoti Small-Cap Virtual Conference on December 5th with a presentation at 10:45am ET, and the Benchmark Company 13th Annual Discovery One-on-One Investor Conference in New York on December 11th. Senior management, including CEO Dr. Cheryl Blanchard and CFO Steve Griffin, will conduct one-on-one investor meetings throughout these events.
Arthrosurface, a leading provider of joint restoration and preservation solutions, has been acquired from Anika Therapeutics (NASDAQ: ANIK) by Primo Medical Group executives and former Arthrosurface leaders. The company specializes in minimally invasive techniques with a portfolio of over 150 different surface implant curvatures for knee, shoulder, wrist, and toe treatments. Under new ownership through Phoenix Brio, Arthrosurface will maintain its operations in West Bridgewater, Massachusetts, with no expected disruption to product access or customer service.
Anika Therapeutics (ANIK) reported Q3 2024 revenue of $38.8 million, down 7% year-over-year. The company announced the sale of Arthrosurface and planned divestiture of Parcus Medical to focus on OA Pain Management and Regenerative Solutions. Key highlights: U.S. OA Pain Management revenue declined 5%, while Regenerative Solutions grew 17%, led by the Integrity Implant System's 40%+ sequential growth. Net loss was $29.9 million or $2.03 per share. The company will now categorize revenue into OEM Channel and Commercial Channel, with Commercial Channel on track for ~17% CAGR since 2021. First module of Hyalofast PMA was filed in October, targeting U.S. launch by 2026.
